RATIONALE: Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-β super family of secreted factors. A recent study showed that reduced GDF11 blood levels with aging was associated with pathological cardiac hypertrophy (PCH) and restoring GDF11 to normal levels in old mice rescued PCH. OBJECTIVE: To determine whether and by what mechanism GDF11 rescues aging dependent PCH. METHODS AND RESULTS: Twenty-four-month-old C57BL/6 mice were given a daily injection of either recombinant (r) GDF11 at 0.1 mg/kg or vehicle for 28 days. rGDF11 bioactivity was confirmed in vitro. After treatment, rGDF11 levels were significantly increased, but there was no significant effect on either heart weight or body weight. Heart weight/body weight ratios of old mice were not different from 8- or 12-week-old animals, and the PCH marker atrial natriuretic peptide was not different in young versus old mice. Ejection fraction, internal ventricular dimension, and septal wall thickness were not significantly different between rGDF11 and vehicle-treated animals at baseline and remained unchanged at 1, 2, and 4 weeks of treatment. There was no difference in myocyte cross-sectional area rGDF11 versus vehicle-treated old animals. In vitro studies using phenylephrine-treated neonatal rat ventricular myocytes, to explore the putative antihypertrophic effects of GDF11, showed that GDF11 did not reduce neonatal rat ventricular myocytes hypertrophy, but instead induced hypertrophy. CONCLUSIONS: Our studies show that there is no age-related PCH in disease-free 24-month-old C57BL/6 mice and that restoring GDF11 in old mice has no effect on cardiac structure or function.
RATIONALE: Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-β super family of secreted factors. A recent study showed that reduced GDF11 blood levels with aging was associated with pathological cardiac hypertrophy (PCH) and restoring GDF11 to normal levels in old mice rescued PCH. OBJECTIVE: To determine whether and by what mechanism GDF11 rescues aging dependent PCH. METHODS AND RESULTS: Twenty-four-month-old C57BL/6 mice were given a daily injection of either recombinant (r) GDF11 at 0.1 mg/kg or vehicle for 28 days. rGDF11 bioactivity was confirmed in vitro. After treatment, rGDF11 levels were significantly increased, but there was no significant effect on either heart weight or body weight. Heart weight/body weight ratios of old mice were not different from 8- or 12-week-old animals, and the PCH marker atrial natriuretic peptide was not different in young versus old mice. Ejection fraction, internal ventricular dimension, and septal wall thickness were not significantly different between rGDF11 and vehicle-treated animals at baseline and remained unchanged at 1, 2, and 4 weeks of treatment. There was no difference in myocyte cross-sectional area rGDF11 versus vehicle-treated old animals. In vitro studies using phenylephrine-treated neonatal rat ventricular myocytes, to explore the putative antihypertrophic effects of GDF11, showed that GDF11 did not reduce neonatal ratventricular myocytes hypertrophy, but instead induced hypertrophy. CONCLUSIONS: Our studies show that there is no age-related PCH in disease-free 24-month-old C57BL/6 mice and that restoring GDF11 in old mice has no effect on cardiac structure or function.
Authors: Irina M Conboy; Michael J Conboy; Amy J Wagers; Eric R Girma; Irving L Weissman; Thomas A Rando Journal: Nature Date: 2005-02-17 Impact factor: 49.962
Authors: Stephanie A Parsons; Douglas P Millay; Michelle A Sargent; Elizabeth M McNally; Jeffery D Molkentin Journal: Am J Pathol Date: 2006-06 Impact factor: 4.307
Authors: Dana S Mosher; Pascale Quignon; Carlos D Bustamante; Nathan B Sutter; Cathryn S Mellersh; Heidi G Parker; Elaine A Ostrander Journal: PLoS Genet Date: 2007-04-30 Impact factor: 5.917
Authors: Tommaso Poggioli; Ana Vujic; Peiguo Yang; Claudio Macias-Trevino; Aysu Uygur; Francesco S Loffredo; James R Pancoast; Miook Cho; Jill Goldstein; Rachel M Tandias; Emilia Gonzalez; Ryan G Walker; Thomas B Thompson; Amy J Wagers; Yick W Fong; Richard T Lee Journal: Circ Res Date: 2015-10-21 Impact factor: 17.367
Authors: Marianne Pons; Leonidas G Koniaris; Sharon M Moe; Juan C Gutierrez; Aurora Esquela-Kerscher; Teresa A Zimmers Journal: Surgery Date: 2018-05-03 Impact factor: 3.982
Authors: Anil K Padyana; Bhamini Vaidialingam; David B Hayes; Priyanka Gupta; Michael Franti; Neil A Farrow Journal: Acta Crystallogr F Struct Biol Commun Date: 2016-02-16 Impact factor: 1.056
Authors: Shavonn C Harper; Jaslyn Johnson; Giulia Borghetti; Huaqing Zhao; Tao Wang; Markus Wallner; Hajime Kubo; Eric A Feldsott; Yijun Yang; Yunichel Joo; Xinji Gou; Abdel Karim Sabri; Priyanka Gupta; Maria Myzithras; Ashraf Khalil; Michael Franti; Steven R Houser Journal: Circ Res Date: 2018-11-09 Impact factor: 17.367
Authors: Haobo Li; Margaret H Hastings; James Rhee; Lena E Trager; Jason D Roh; Anthony Rosenzweig Journal: Circ Res Date: 2020-02-13 Impact factor: 17.367